IOVA

Iovance Biotherapeutics, Inc.

NasdaqGMUSDEQUITY DELAYED

8.29

▼ 0.70 (7.79%)

MARKET · —

Price

Open

8.99

Prev close

8.99

Day high

9.30

Day low

8.15

Volume

27.70M

Market cap

—

P/E (TTM)

—

52W range

1.76 – 9.36

Trailing performance

Price return · vs SPY

Returnvs SPY

+18.77% +20.1%

+61.60% +57.9%

+124.05% +121.0%

+188.85% +177.8%

YTD

+203.66% +191.4%

+227.67% +207.7%

+20.14% -54.0%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

7.25

+14.30% from price

SMA 20

6.05

+37.00% from price

SMA 50

5.04

+64.36% from price

SMA 100

4.38

+89.29% from price

SMA 200

3.63

+128.57% from price

EMA 12

7.12

+16.36% from price

EMA 26

6.19

+34.02% from price

EMA 50

5.42

+52.86% from price

RSI (14)

72.0

Overbought

MACD (12,26,9)

0.94

Hist 0.26

ATR (14)

0.73

8.81% of price

Realised vol 30D

142.3%

Annualised

Bollinger upper

8.93

20, 2σ

Bollinger lower

3.17

20, 2σ

50 / 200 cross

Golden

5.04 vs 3.63

Trend bias

Above 200

+128.57%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.29

More volatile than market

Correlation to SPY

0.16

Largely independent

Realised vol 30D

142.3%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-39.0%

Peak to trough

Max drawdown 5Y

-94.0%

Peak to trough

ATR 14

0.73

8.81% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 8.29

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

IOVA · links out to the publisher

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire · 18h ago Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? Stocktwits · 1d ago IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism Stocktwits · 2d ago Iovance's Growth Outlook Clouded as Amtagvi Faces Competition Hurdles, UBS Says MT Newswires · 2d ago Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy Zacks · 2d ago UBS Adjusts Iovance Biotherapeutics Price Target to $7 From $4, Maintains Neutral Rating MT Newswires · 2d ago IOVA Stock Hits New 52-Week High As Shares Jump 14% — What Drove The Rally? Stocktwits · 3d ago Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today? Stocktwits · 4d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.